Adcetris passes Phase III CTCL test

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Adcetris brentuximab vedotin met the primary endpoint in the Phase III ALCANZA study to treat CD30-expressing cutaneous T cell lymphoma in patients who had received prior systemic or radiation therapy. In the 131-patient study, 56.3% of patients receiving Adcetris achieved an objective response lasting at least four months vs. 12.5% of patients receiving investigator's choice of therapy (p<0.0001).

The companies said Adcetris also led to significant improvements vs. control on secondary endpoints that included complete response rate, progression-free survival (PFS) and reduced burden of symptoms during treatment. The companies plan to present the data at the American Society of Hematology meeting in December. ...